The main objective is to quantify the population of reverse migrating neutrophils in patients with COVID-19.
This is a non-interventional transversal research whose main objective is to quantify the population of reverse migrating neutrophils in patients with COVID-19. Design: A multicentric (3 sites) clinical trial Sample size : 200 patients Population concerned: Patients hospitalized in intensive care with SARS-CoV-2 infection confirmed by RT-PCR from a nasopharyngeal swab. Duration of participation (treatment + follow-up): until the patient is discharged from the ICU and within 2 months top. No interim analysis is planned. Analysis will be performed at the end of the study.
Study Type
OBSERVATIONAL
Enrollment
200
Intensive care department, Hôpital Saint Antoine
Paris, France
RECRUITINGPercentage of circulating neutrophils in reverse migration
Percentage of circulating neutrophils in reverse migration determined on a sample taken during the admission of COVID 19 patients to Intensive Care Units by flow cytometry: the samples will be incubated for 45 minutes with anti-human CXCR1, CD11c, CD11b, and CD62L antibodies. Erythrocytes will be lysed and fixed leukocytes will be analyzed by flow cytometry.
Time frame: Within 4 hours following the patient admission in Intensive Care Units (ICU).
Analysis of neutrophils and platelets
The analysis of neutrophils and platelets, and of the inflammatory environment will be carried out on a sample taken on admission of patients to Intensive Care Units 1. Phenotypic and functional analysis of neutrophils * Measurement of the oxidative explosion * Measurement of neutrophil apoptosis * Measurement of intravascular NETosis 2. Analysis of platelet aggregation and activation * Quantification of the fraction of immature platelets (IPF) * Contribution of platelets to clot stiffness * ELISA assay of soluble platelet activation markers * Measurement of D-Dimers, von Willebrand factor, thrombin-antithrombin complex (TAT), α2-Plasmin-Plasmin-inhibitor
Time frame: Within 4 hours following the patient admission in Intensive Care Units (ICU).
SAPS II score
Assessment of the link between phenotypic and functional markers of neutrophils on admission to the ICU. The severity of the disease is determined using clinical scores (SAPS II ("simplified acute physiology") and SOFA ("Sequential Organ Failure Assessment") (global SOFA, respiratory and non-respiratory) scores; these scores will be assessed during the period of hospitalization in Intensive Care Units. An association between these 2 scores (SAPSII and SOFA scores) and the neutrophil markers will be sought.
Time frame: From admission to the follow-up visits (Day 3, Day 7 and as part of usual care every 7 days until the patient is discharged and within 2 months top).
SOFA score
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assessment of the link between phenotypic and functional markers of neutrophils on admission to the ICU. The severity of the disease is determined using clinical scores (SAPS II ("simplified acute physiology") and SOFA ("Sequential Organ Failure Assessment") (global SOFA, respiratory and non-respiratory) scores; these scores will be assessed during the period of hospitalization in Intensive Care Units. An association between these 2 scores (SAPSII and SOFA scores) and the neutrophil markers will be sought.
Time frame: From admission to the follow-up visits (Day 3, Day 7 and as part of usual care every 7 days until the patient is discharged and within 2 months top).
Mortality rate
The mortality occurring within 2 months of admission of patients to an ICU will also be assessed.
Time frame: 2 months